Pregnancy-related acute myocardial infarction after treatment with ritodrine hydrochloride: A case report

Pregnancy-associated myocardial infarction (PAMI) is a rare but potentially life-threatening condition for the mother and fetus. Pregnancy also confers a three- to fourfold increased risk of MI compared with the non-pregnant state. However, recognizing PAMI promptly in obstetric settings remains challenging. A 34-year-old Japanese primigravida at 30 weeks of gestation had been receiving ritodrine for preterm labor. On hospital day 2, approximately 4 h after discontinuation of tocolytics, repeat electrocardiography (ECG) indicated new ST-segment elevation in leads I, aVL, and V3-V6 without chest pain. High-sensitivity troponin I was 5392 pg/mL, CK-MB was 21 IU/L, and transthoracic ECG revealed mild apical hypokinesis. That night, prolonged fetal bradycardia prompted emergency Cesarean delivery. Maternal cardiac biomarkers then declined rapidly, and the ECG and wall-motion abnormalities resolved. Myocardial perfusion scintigraphy (day 5) and coronary computed tomography angiography (day 6) showed no perfusion defect or obstructive coronary disease. The infant, weighing 1546 g, was admitted to the neonatal intensive care unit. No adverse effects attributable to ritodrine were observed, and the infant was discharged on postnatal day 58. The report describes probable drug-induced PAMI temporally associated with β₂-agonist tocolysis, with plausible mechanisms including transient coronary vasospasm and supply-demand mismatch in the hemodynamic milieu of pregnancy. This case suggests that women receiving β₂-agonist tocolysis should be monitored for vital signs, electrolytes, and ECG changes. Even without chest pain, new ECG abnormalities or palpitations warrant immediate cardiac evaluation. • In the reported case silent myocardial infarction occurred during ritodrine tocolysis for threatened preterm labor. • Electrocardiography, echocardiography, and high-sensitivity troponin identified myocardial injury. • Careful cardiac monitoring should be considered when using ritodrine in pregnancy.

Authors

Institutions

Publication Details

Journal
Case Reports in Women s Health
Published
2026-03-22
DOI
https://doi.org/10.1016/j.crwh.2026.e00804
Primary Topic
Cardiovascular Issues in Pregnancy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pregnancy-related acute myocardial infarction after treatment with ritodrine hydrochloride: A case report

Naofumi Yamane, Maiko Sagawa, Shina Harimoto, Hiroko Nakamura et al.
Case Reports in Women s Health
Cardiovascular Issues in Pregnancy
article

Pregnancy-related acute myocardial infarction after treatment with ritodrine hydrochloride: A case report

Naofumi Yamane, Maiko Sagawa, Shina Harimoto, Hiroko Nakamura, Yumiko Kan, Megumi Tsunakake, Sayaka Yamada, Masatoshi Kumagai, Hikari Sanada
article en

Abstract

Pregnancy-associated myocardial infarction (PAMI) is a rare but potentially life-threatening condition for the mother and fetus. Pregnancy also confers a three- to fourfold increased risk of MI compared with the non-pregnant state. However, recognizing PAMI promptly in obstetric settings remains challenging. A 34-year-old Japanese primigravida at 30 weeks of gestation had been receiving ritodrine for preterm labor. On hospital day 2, approximately 4 h after discontinuation of tocolytics, repeat electrocardiography (ECG) indicated new ST-segment elevation in leads I, aVL, and V3-V6 without chest pain. High-sensitivity troponin I was 5392 pg/mL, CK-MB was 21 IU/L, and transthoracic ECG revealed mild apical hypokinesis. That night, prolonged fetal bradycardia prompted emergency Cesarean delivery. Maternal cardiac biomarkers then declined rapidly, and the ECG and wall-motion abnormalities resolved. Myocardial perfusion scintigraphy (day 5) and coronary computed tomography angiography (day 6) showed no perfusion defect or obstructive coronary disease. The infant, weighing 1546 g, was admitted to the neonatal intensive care unit. No adverse effects attributable to ritodrine were observed, and the infant was discharged on postnatal day 58. The report describes probable drug-induced PAMI temporally associated with β₂-agonist tocolysis, with plausible mechanisms including transient coronary vasospasm and supply-demand mismatch in the hemodynamic milieu of pregnancy. This case suggests that women receiving β₂-agonist tocolysis should be monitored for vital signs, electrolytes, and ECG changes. Even without chest pain, new ECG abnormalities or palpitations warrant immediate cardiac evaluation. • In the reported case silent myocardial infarction occurred during ritodrine tocolysis for threatened preterm labor. • Electrocardiography, echocardiography, and high-sensitivity troponin identified myocardial injury. • Careful cardiac monitoring should be considered when using ritodrine in pregnancy.

Case Reports in Women s HealthVol. 50
Hiroshima University Hospital (JP), National Hospital Organization (JP), Kure Medical Center (JP)
Good health and well-being
Openalex Percentile: Top 22%
Cardiovascular Issues in Pregnancy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.